AVERAGE TREATMENT THAT UNDERSTANDS THE ENTERED ADMINISTRATION OF EDARAVONA

摘要

the invention relates to a solid pharmaceutical composition dispersible in water for use in the treatment of an illness, said treatment comprising dispersing the pharmaceutical composition in an aqueous liquid to produce an enteric-administered liquid containing at least 0.5 grams of the pharmaceutical composition and at least 0.3 g / l of edaravone, followed by enteral administration of the liquid capable of being entericly administered to a human patient in an amount that provides a dose of 30-300 mg edaravone, with said pharmaceutical composition comprising: 2-50%, by weight, of 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone); and 3-50%, by weight, of water-soluble alkalizing agent. this solid edaravone-containing composition can be easily dispersed in aqueous liquid to prepare an aqueous solution of edaravone that can be ingested by a patient. the solid composition of the present invention offers the advantage that edaravone dissolves very quickly when the composition is introduced into water and that the enterally administrable liquid thus obtained has high oral bioavailability.